Treatment for bacterial infections

Details Treatment for bacterial infections Treatment for bacterial infections

2005-07-01

2009-10-27

Mondesi, Robert B (Department: 1645)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Binds bacterium or component thereof or substance produced...

C424S130100, C424S141100, C424S150100, C424S164100, C530S350000

Reexamination Certificate

active

07608265

ABSTRACT:
The present invention is concerned with compounds, medicaments and treatments forClostridium difficileinfection, together with novel isolated antibodies and their use in same. The present invention is also concerned with the treatment and prophylaxis ofE. faeciumandE. faecalisinfection and provides medicaments and treatments for same.

REFERENCES:
patent: 6291158 (2001-09-01), Winter et al.
patent: 6667035 (2003-12-01), Von Eichel-Streiber et al.
patent: 0 368 684 (1990-05-01), None
patent: 0 376 851 (1990-07-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 97/20932 (1997-06-01), None
patent: WO 00/12562 (2000-03-01), None
patent: WO 01/44300 (2000-06-01), None
patent: WO 01/27279 (2001-04-01), None
patent: WO 01/96599 (2001-12-01), None
patent: WO 02/055559 (2002-07-01), None
patent: WO 02/062379 (2002-08-01), None
patent: WO 03/048321 (2003-06-01), None
patent: WO 03/052416 (2003-06-01), None
patent: WO 2004/094474 (2004-11-01), None
Wiesenborn et al. Applied and Environmental Microbiology, Nov. 1988, p. 2717-2722.
Vajdos et al. (J. Mol. Biol. 2002. 320:415-428).
De Pascalis et al (The Journal of Immunology. 2002 169: 3076-3084).
MacCallum et al (J. Mol. Biol. 1996, 262: 732-745.
Bendig (Methods: A Companion to Methods in Enzymology 1995; 8:83-93).
Sliwkowski et al., “Incorporation and Distribution of Selenium Into Thiolase From Clostridium-Kluyveri”, Journal of Biological Chemistry, 260(5): 3140-3144 (1985).
Winzer et al., “Differential Regulation of Two Thiolase Genes from Clostridum acetobutylicum DSM 792”, Journal of Molecular Microbiology and Biotechnology 2(4): 531-541 (2000).
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue”J. Cell Biology111:2129-2138 (1990).
Burgoon et al., “Cloning the Antibody Response in Humans with Inflammatory Central Nervous System Disease: Analysis of the Expressed IgG Repertoire in Subacute Schlerosing Panencephalitis Brain Reveals Disease-Relevant Antibodies That Recognize Specific Measles Virus Antigens”J. Immunol.163(6):3496-3502 (1999).
Casset et al., “A peptide Mimetic of an anti-CD4 monoclonal antibody by rational design”BBRC307:198-205 (2003).
Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen”J. Mol. Biol.293:865-881 (1999).
Colman “Effects of amino acid sequence changes on antibody-antigen interactions”Res. in Immunol.145:33-36 (1994).
Currier et al., “Mitogens, Superantigens, and Nominal Antigens Elicit Distinctive Patterns of TCRB CDR3 Diversity”Human Immunol.48:39-51 (1996).
Desiderio et al., “A Semi-synthetic Repertoire of Intrinsically Stable Antibody Fragments Derived from a Single-framework Scaffold”J. Mol. Biol.310:603-615 (2001).
Holm et al., “Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1”Mol. Immunol.44:1075-1084 (2007).
Holt et al., “Domain antibodies: proteins for therapy”Trends in Biotechnology21(11):484-490 (2003).
Lazar et al , “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results • in Different Biological Activities”Mol. Cell. Biol.8(3):1247-1252 (1988).
Lewis et al., “Use of a Novel Mutagenesis Strategy, Optimized Residue Substitution, to Decrease the Off-Rate of an Anti-gp120 Antibody”Mol. Immunol.32(14/15):1065-1072 (1995).
Lin et al., “Structure-Function Relationships in Glucagon: Properties of Highly Purified Dis-His1-, Monoiodo-, and [Des-Asn28, Thr29] (homoserine lactone27)-glucagon”Biochem. USA14:1559-1563 (1975).
Nie et al.,“ Immunization with immune complex alters the repertoire of antigen-reactive B cells in the germinal centers”Eur. J. Immunol.27(12):3517-3525 (1997).
Panka et al., “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies”PNAS USA85:3080-3084, 1988.
Rinaldi et al., “Antibodies Elicited by Naked DNA Vaccination Against the Complementary-determining Region 3 Hypervariable Region of Immunoglobulin Heavy Chain Idiotypic Determinants of B-lymphoproliferative Disorders Specifically React with Patients' Tumor Cells”Cancer Res.61:1555-1568 (2001).
Rinaldi et al., “Strategies to Elicit Anti-Idiotypic Immune Response in B-Lymphoma Patients”Gene Therapy of Canceredited by Walden et al. Plenum Press, New York, 323-330 (1998).
Rudikoff et al, “Single amino acid substitution altering antigen-binding specificity”PNAS USA.,79(6):1979-1983 (1982).
Schwartz et al., “A superactive insulin: [B10-Aspartic acid]insulin(human)”PNAS USA84:6408- 6411 (1987).
Wen et al., “In-vivo immune response to idiotypic VH complementarity-determining region 3 peptide vaccination in B-cell non-Hodgkins lymphoma”British J. Haematology103:663-668 (1998).
White et al, “Analysis of Immunoglobulin (Ig) Isotype Diversity and IgM/D Memory in the Response to Phenyl-Oxazolone”J. Exp. Med.191(12):2209-2219 (2000).

Affiliated with

Also associated with

Rating

Treatment for bacterial infections does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment for bacterial infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for bacterial infections will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4068431